Seeking Alpha

Celgene (CELG -6.4%) dips after missing Q1 estimates on all counts despite solid sales growth...

Celgene (CELG -6.4%) dips after missing Q1 estimates on all counts despite solid sales growth and better margins. Net earnings actually jumped 57% Y/Y on strong sales of its flagship blood-cancer treatment Revlimid. Separately, the company says it's entered into a strategic partnership with privately held Epizyme to develop personalized therapies for patients with genetically defined cancers.
Comments (1)
  • tebert4
    , contributor
    Comments (4) | Send Message
     
    Based on estimated earnings of $4.80 for the current fiscal year, Celgene is trading at a P/E ratio of 15.2, well below its average of 23 during 2011. In spite of missing both revenues and earnings estimates, the stock turned in a stellar quarter and reaffirmed guidance for 2012. With a modest P/E of 18 the stock could be valued at $86.40 by year end, an upside of 20%.This looks like a buying opportunity to me.
    Disclosure: I am long CELG
    26 Apr 2012, 06:31 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|